GH Research’s (GHRS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of GH Research (NASDAQ:GHRS) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $40.00 target price on the stock.

Separately, Canaccord Genuity Group dropped their price target on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $8.57 on Friday. GH Research has a 1 year low of $5.50 and a 1 year high of $14.99. The firm has a 50-day moving average of $8.44 and a 200 day moving average of $9.20. The stock has a market cap of $445.88 million, a P/E ratio of -10.85 and a beta of 0.84.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its holdings in GH Research PLC (NASDAQ:GHRS) by 1.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).